Solu-Medrol Alternatives Compared
| Solu-Medrol (methylprednisolone) | Nucala (mepolizumab) | Xolair (omalizumab) |
|
|---|
| Solu-Medrol (methylprednisolone) | Nucala (mepolizumab) | Xolair (omalizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Allergic Rhinitis, Asthma, Allergies, Congenital Adrenal Hyperplasia, Asthma - Maintenance, Asthma - acute, Dermatologic Lesion, Gout - Acute, Immunosuppression, Inflammatory... View more |
Prescription only
Nucala is a biologic that works by blocking the action of IL-5 which is the main cytokine responsible for the survival and production of eosinophils. Nucala may be used to treat severe eosinophilic... View more |
Prescription only
Xolair is an injectable preparation that works by preventing IgE from binding to IgE receptors on mast cells and basophils and may be used to treat allergic asthma, nasal polyps, chronic idiopathic... View more |
Related suggestions Asthma, Maintenance
Popular comparisons
|
|||||||||||||||
| More about Solu-Medrol (methylprednisolone) | More about Nucala (mepolizumab) | More about Xolair (omalizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Solu-Medrol has an average rating of 7.8 out of 10 from a total of 16 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 13% reported a negative effect. |
Nucala has an average rating of 7.3 out of 10 from a total of 100 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 16% reported a negative effect. |
Xolair has an average rating of 7.6 out of 10 from a total of 231 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 18% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Solu-Medrol side effects |
View all Nucala side effects |
View all Xolair side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Solu-Medrol prices |
View all Nucala prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other methylprednisolone brands include: Depo-Medrol, Medrol, Medrol Dosepak, MethylPREDNISolone Dose Pack |
N/A |
Other omalizumab brands include: Omlyclo | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
3.5 hours |
528 hours |
624 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
Excluding First Trimester
Category D
Positive evidence of risk
First Trimester See the full pregnancy warnings document. |
Category N
Not classified
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 630 drugs are known to interact with Solu-Medrol:
|
A total of 26 drugs are known to interact with Nucala:
|
A total of 32 drugs are known to interact with Xolair:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 18, 1959 |
November 04, 2015 |
June 20, 2003 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.